Ann Hynes
Stock Analyst at Mizuho
(4.00)
# 2
Out of 4,829 analysts
245
Total ratings
82.98%
Success rate
690.23%
Average return
Main Sectors:
Stocks Rated by Ann Hynes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UNH UnitedHealth Group | Maintains: Outperform | $600 → $650 | $378.56 | +71.70% | 17 | Apr 9, 2025 | |
| DGX Quest Diagnostics | Maintains: Outperform | $178 → $189 | $175.78 | +7.52% | 14 | Apr 9, 2025 | |
| MOH Molina Healthcare | Maintains: Outperform | $376 → $400 | $327.58 | +22.11% | 8 | Apr 9, 2025 | |
| MEDP Medpace Holdings | Maintains: Outperform | $400 → $355 | $314.09 | +13.02% | 2 | Apr 9, 2025 | |
| IQV IQVIA Holdings | Maintains: Outperform | $242 → $210 | $156.02 | +34.60% | 11 | Apr 9, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $238 → $200 | $139.94 | +42.92% | 14 | Apr 9, 2025 | |
| HUM Humana | Maintains: Outperform | $305 → $316 | $252.53 | +25.13% | 8 | Apr 9, 2025 | |
| FTRE Fortrea Holdings | Maintains: Neutral | $12 → $10 | $5.19 | +92.68% | 2 | Apr 9, 2025 | |
| ELV Elevance Health | Maintains: Outperform | $455 → $505 | $416.69 | +21.19% | 4 | Apr 9, 2025 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $175 → $155 | $142.99 | +8.40% | 2 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $76 | $64.82 | +17.25% | 10 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $14.84 | +21.29% | 2 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $48 → $37 | $25.89 | +42.94% | 10 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $15 | $14.35 | +4.57% | 11 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $110 → $120 | $148.58 | -19.24% | 8 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $20 | $22.35 | -10.51% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $21.67 | +29.21% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 → $130 | $154.61 | -15.92% | 14 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $95 | $116.83 | -18.69% | 8 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $370 → $385 | $315.41 | +22.06% | 10 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $200 | $191.57 | +4.40% | 15 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $242 → $268 | $1.99 | +13,367.34% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $450 → $505 | $685.18 | -26.30% | 19 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $257 → $230 | $251.01 | -8.37% | 15 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $325 → $275 | $363.28 | -24.30% | 20 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $31 → $25 | $11.40 | +119.30% | 8 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $50 | $23.24 | +115.19% | 2 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $76 | $62.86 | +20.91% | 7 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $57 | $1.52 | +3,650.00% | 1 | Sep 21, 2017 |
UnitedHealth Group
Apr 9, 2025
Maintains: Outperform
Price Target: $600 → $650
Current: $378.56
Upside: +71.70%
Quest Diagnostics
Apr 9, 2025
Maintains: Outperform
Price Target: $178 → $189
Current: $175.78
Upside: +7.52%
Molina Healthcare
Apr 9, 2025
Maintains: Outperform
Price Target: $376 → $400
Current: $327.58
Upside: +22.11%
Medpace Holdings
Apr 9, 2025
Maintains: Outperform
Price Target: $400 → $355
Current: $314.09
Upside: +13.02%
IQVIA Holdings
Apr 9, 2025
Maintains: Outperform
Price Target: $242 → $210
Current: $156.02
Upside: +34.60%
ICON Public Limited Company
Apr 9, 2025
Maintains: Outperform
Price Target: $238 → $200
Current: $139.94
Upside: +42.92%
Humana
Apr 9, 2025
Maintains: Outperform
Price Target: $305 → $316
Current: $252.53
Upside: +25.13%
Fortrea Holdings
Apr 9, 2025
Maintains: Neutral
Price Target: $12 → $10
Current: $5.19
Upside: +92.68%
Elevance Health
Apr 9, 2025
Maintains: Outperform
Price Target: $455 → $505
Current: $416.69
Upside: +21.19%
Charles River Laboratories International
Apr 9, 2025
Maintains: Neutral
Price Target: $175 → $155
Current: $142.99
Upside: +8.40%
Apr 9, 2025
Maintains: Outperform
Price Target: $70 → $76
Current: $64.82
Upside: +17.25%
Apr 9, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $14.84
Upside: +21.29%
Mar 25, 2025
Maintains: Neutral
Price Target: $48 → $37
Current: $25.89
Upside: +42.94%
Nov 19, 2024
Maintains: Neutral
Price Target: $13 → $15
Current: $14.35
Upside: +4.57%
Nov 4, 2024
Maintains: Neutral
Price Target: $110 → $120
Current: $148.58
Upside: -19.24%
Nov 4, 2024
Maintains: Outperform
Price Target: $17 → $20
Current: $22.35
Upside: -10.51%
Aug 19, 2024
Initiates: Outperform
Price Target: $28
Current: $21.67
Upside: +29.21%
May 1, 2024
Reiterates: Buy
Price Target: $118 → $130
Current: $154.61
Upside: -15.92%
Apr 25, 2024
Maintains: Buy
Price Target: $93 → $95
Current: $116.83
Upside: -18.69%
Mar 8, 2024
Maintains: Buy
Price Target: $370 → $385
Current: $315.41
Upside: +22.06%
Mar 6, 2024
Maintains: Buy
Price Target: $175 → $200
Current: $191.57
Upside: +4.40%
Feb 23, 2024
Maintains: Buy
Price Target: $242 → $268
Current: $1.99
Upside: +13,367.34%
Feb 9, 2024
Maintains: Neutral
Price Target: $450 → $505
Current: $685.18
Upside: -26.30%
Oct 31, 2023
Maintains: Buy
Price Target: $257 → $230
Current: $251.01
Upside: -8.37%
Oct 25, 2023
Maintains: Buy
Price Target: $325 → $275
Current: $363.28
Upside: -24.30%
Oct 10, 2023
Maintains: Neutral
Price Target: $31 → $25
Current: $11.40
Upside: +119.30%
Jul 11, 2023
Maintains: Buy
Price Target: $48 → $50
Current: $23.24
Upside: +115.19%
Jul 11, 2023
Maintains: Neutral
Price Target: $80 → $76
Current: $62.86
Upside: +20.91%
Sep 21, 2017
Initiates: Neutral
Price Target: $57
Current: $1.52
Upside: +3,650.00%